BIODLINK-B (01875) experienced a significant surge during intraday trading, with its stock price soaring 11.09%.
The sharp increase follows the announcement that WUXI XDC's cash offer to acquire BIODLINK has received valid acceptance for 60% of the company's equity, making the share offer officially effective. This controlling stake acquisition will enable WUXI XDC to enrich its project portfolio, expand its customer base, enhance production capacity allocation, and solidify its leading position in the global ADC CRDMO field.
According to Hong Kong Stock Exchange disclosures, WuXi XDC Cayman Inc. acquired 464 million ordinary shares of BIODLINK off-market at an average price of HK$4.0 per share in a transaction valued at approximately HK$1.855 billion, increasing its shareholding from 0.00% to 60.00%.